#Erlow - Twitter Hashtag

3 months ago · Chicago

#ASCO26 Thank you @dr_yakupergun for highlighting our work showing the unmet need in the management of ER-low MBC, 1st line CDK4/6i should NOT be considered a default choice for this small but important group. @jeffreychchan #bcsm #ERlow

Yakup Ergün

@dr_yakupergun

3 months ago

#ASCO26 Does CDK4/6i really work in ER-low disease? I had also really wanted to study the efficacy of CDK4/6 inhibitors in ER-low tumors, but I could not collect enough data. This study addresses exactly this important question. First of all, congratulations to the investigators. In ER-low HR+/HER2− MBC, CDK4/6i + ET does not seem to deliver the expected HR+ benefit: PFS was 2.9 months. In ER-high patients, PFS was 23.3 months. Despite the small sample size and the inherent limitations of a retrospective study, the observed behavior is consistent with what we would expect from ER-low tumors. ER-low disease should not simply be placed into the classic HR+ category with automatic CDK4/6i + ET. This subtype behaves closer to TNBC.

dr_yakupergun's tweet photo. #ASCO26

Does CDK4/6i really work in ER-low disease?

I had also really wanted to study the efficacy of CDK4/6 inhibitors in ER-low tumors, but I could not collect enough data. This study addresses exactly this important question. First of all, congratulations to the investigators.

In ER-low HR+/HER2− MBC, CDK4/6i + ET does not seem to deliver the expected HR+ benefit: PFS was 2.9 months. In ER-high patients, PFS was 23.3 months.

Despite the small sample size and the inherent limitations of a retrospective study, the observed behavior is consistent with what we would expect from ER-low tumors. ER-low disease should not simply be placed into the classic HR+ category with automatic CDK4/6i + ET. This subtype behaves closer to TNBC.

3

77

27

42

5K

0

2

1

3

920

Kristina Jankovic, MD @JankovicK

over 1 year ago

⚠️ Retrospective analysis of >7,000 pts with high-risk #ERlow (1–10%) early #BreastCancer 🎀 shows that omission of adjuvant ET is linked to worse OS - especially in ER 6–10% or with residual disease after NAC ⚠️ 👉 https://t.co/zJP4okn7g5 @OncoAlert @JCO_ASCO

JankovicK's tweet photo. ⚠️ Retrospective analysis of >7,000 pts with high-risk #ERlow (1–10%) early #BreastCancer 🎀 shows that omission of adjuvant ET is linked to worse OS - especially in ER 6–10% or with residual disease after NAC ⚠️

👉 https://t.co/zJP4okn7g5
@OncoAlert @JCO_ASCO https://t.co/uKlcdsoooP

2

97

36

40

15K

Erika Hamilton, MD, FASCO @ErikaHamilton9

almost 2 years ago

It still frustrates me that most often these patients are excluded from #TNBC trials....they behave like TNBC not ER+! #access #underserved #ERlow #ESMO24 #ESMOAmbassadors

Luca Visani @LucaVisani2

almost 2 years ago

Another important confirmation that ER-low breast cancer should be treated as triple negative! #ESMO2024 #ESMO24 #breastcancer

LucaVisani2's tweet photo. Another important confirmation that ER-low breast cancer should be treated as triple negative! #ESMO2024 #ESMO24 #breastcancer https://t.co/Jv3O3cd6tv

0

1

0

2K

0

20

4

2

2K

Kelvin Bao @khkbao

over 2 years ago · Chicago

ER low as a separate entity compare with other ER+ tumours, RW database analysis shows that adjuvant ET is still important! #ERlow #ASCO24 #bcsm

khkbao's tweet photo. ER low as a separate entity compare with other ER+ tumours, RW database analysis shows that adjuvant ET is still important!
#ERlow #ASCO24 #bcsm https://t.co/0WdBLPcSdf

0

3

1

0

166

BreastCancerTrials.org @BCTrials

about 5 years ago

1/3 IMPORTANT TOPIC! Some #ClinicalTrials do enroll ppl w/"ER-Low" (usually defined as < 10%, sometimes < 5%) to enroll in trials "designed" for people with #TNBC. We include this information in trial titles because it is often buried in the inclusion criteria. #bcsm #ERLow

Stephanie Graff, MD, FACP, FASCO @DrSGraff

about 5 years ago

This is why we need to rethink #clinicaltrial eligibility to be inclusive of HR low patients in #TNBC trials for optimal patient outcomes #bcsm

4

32

3

2

0

1

3

0

Eletro Vibez @eletro_vibez

over 5 years ago

QUE SAUDADES DE UM TECH HOUSE #TbtVibez 🗣️🗣️ Quem se lembra da #erlow 2019? Um verdadeiro baile para os amantes de #TechHouse, não é mesmo!?🤩🤯

0

12

2

0

BreastCancerTrials.org @BCTrials

about 6 years ago

August's Metastatic Trial Talk: Sexual side effects of #MBC treatment #Metastatic breast cancer in the older person ER-low #breastcancer (Did you know some #TNBC trials allow ppl with ER-low disease?) https://t.co/IWp8A6XDKx #bcsm #clinicaltrials #cancerdemama #gerionc #ERlow

0

4

1

0